Health
Telehealth startups and federal policy shifts drive surge in perimenopause hormone therapy
Regulatory updates and venture-backed virtual clinics have expanded access to hormone treatments, sparking debate among medical experts over potential overtreatment.
The short version
- Web traffic to top perimenopause telehealth platforms increased by 490 percent between 2023 and 2026 following regulatory changes and broader public interest.
- Federal health officials backed policy shifts, including the FDA removing black box warnings from hormone therapy formulations.
- Medical experts warn that aggressive marketing risks over-attributing ordinary life stressors and general symptoms to hormone imbalances.
Key facts
- A SimilarWeb analysis showed web traffic to perimenopause startups Midi, Winona, Alloy, and Evernow grew by 490 percent from 2023 to 2026.[Wired]
- The U.S. Food and Drug Administration removed black box warnings from hormone therapy products.[Wired]
- HHS Secretary Robert F. Kennedy Jr. and ARPA-H Director Alicia Jackson publicly advocated for updated, evidence-based approaches to hormone therapy.[Wired]
- Prominent gynecologists and medical directors, including Mayo Clinic's Stephanie Faubion, cautioned that wide-ranging symptom lists could lead to unnecessary hormone prescriptions.[Wired]
What remains uncertain
- Medical experts disagree on the optimal timing for starting hormone therapy and whether non-specific symptoms like fatigue or anxiety are directly tied to perimenopausal hormone fluctuations.[Wired]
Sources
- Inside the Perimenopause Industrial ComplexWired metered